Pfizer Inc said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorization of Lyrica® (pregabalin), a novel mechanism for the treatment of generalized anxiety disorder (GAD) in adults. Jan 28, 2006 - 12:37:00 PM